These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21210843)

  • 1. Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
    Cattaneo D; Meraviglia P; Cozzi V; Baldelli S; Milani G; Clementi E
    Fundam Clin Pharmacol; 2012 Apr; 26(2):204-6. PubMed ID: 21210843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evidence-based therapeutic drug monitoring of atazanavir].
    Solas C; Muret P;
    Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
    Feldt T; Oette M; Kroidl A; Göbels K; Leidel R; Sagir A; Kuschak D; Häussinger D
    Eur J Med Res; 2005 Jan; 10(1):7-10. PubMed ID: 15737947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
    Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
    Guaraldi G; Cocchi S; Motta A; Ciaffi S; Codeluppi M; Bonora S; Di Benedetto F; Masetti M; Floridia M; Baroncelli S; Pinetti D; D'Avolio A; Bertolini A; Esposito R
    J Antimicrob Chemother; 2008 Dec; 62(6):1356-64. PubMed ID: 18776190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
    Else LJ; Jackson V; Brennan M; Back DJ; Khoo SH; Coulter-Smith S; Lambert JS
    HIV Med; 2014 Nov; 15(10):604-10. PubMed ID: 24825070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
    Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
    Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
    Crutchley RD; Ma Q; Sulaiman A; Hochreitter J; Morse GD
    J Pharm Pract; 2011 Apr; 24(2):216-22. PubMed ID: 21712217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
    Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
    Zhu L; Butterton J; Persson A; Stonier M; Comisar W; Panebianco D; Breidinger S; Zhang J; Bertz R
    Antivir Ther; 2010; 15(8):1107-14. PubMed ID: 21149917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.